Viridian Therapeutics的股价在盘前交易时段飙升10.8%，此前该公司用于治疗甲状腺眼病的药物获得了美国食品药品监督管理局的批准。这一监管绿灯为该公司核心产品线的商业化铺平了道路，标志着其在应对这一自身免疫性疾病方面取得了关键进展。市场对此消息反应积极，投资者情绪显著提振。
Viridian Therapeutics的股价在盘前交易时段飙升10.8%，此前该公司用于治疗甲状腺眼病的药物获得了美国食品药品监督管理局的批准。这一监管绿灯为该公司核心产品线的商业化铺平了道路，标志着其在应对这一自身免疫性疾病方面取得了关键进展。市场对此消息反应积极，投资者情绪显著提振。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.